title: Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer.
authors.affiliation: Medical Oncology Unit, University of Siena, Siena - Italy.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen